SEARCH

SEARCH BY CITATION

References

  • 1
    Krupitsky E., Nunes E. V., Ling W., Gastfriend D. R., Memisoglu A., Silverman B. L. Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness. Addiction 2013; 108: 16281637.
  • 2
    Krupitsky E., Nunes E. V., Ling W., Illeperuma A., Gastfriend D. R., Silverman B. L. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo controlled, multicentre randomised trial. Lancet 2011; 377: 15061513.
  • 3
    Kunøe N., Lobmaier P., Vederhus J., Hjerkinn B., Hegstad S., Gossop M. et al. Naltrexone implants after in-patient treatment for opioid dependence: randomised controlled trial. Br J Psychiatry 2009; 194: 541546.
  • 4
    Miotto K., McCann M. J., Rawson R. A., Frosch D., Ling W. Overdose, suicide attempts and death among a cohort of naltrexone-treated opioid addicts. Drug Alcohol Depend 1997; 45: 131134.
  • 5
    Bell J., Trinh L., Butler B., Randall D., Rubin G. Comparing retention in treatment and mortality in people after initial entry to methadone and buprenorphine treatment. Addiction 2009; 104: 11931200.
  • 6
    Teesson M., Mills K., Ross J., Darke S., Williamson A., Havard A. The impact of treatment on 3 years' outcome for heroin dependence: findings from the Australian Treatment Outcome Study (ATOS). Addiction 2007; 103: 8088.
  • 7
    Hser Y., Hoffman V., Grella C., Anglin M. D. A 33-year follow-up of narcotic addicts. Arch Gen Psychiatry 2001; 58: 503508.
  • 8
    Marsden J., Eastwood B., Bradbury C., Dale-Perera A., Farrell M., Hammond P. et al. Effectiveness of community treatments for heroin and crack cocaine addiction in England: a prospective, in-treatment cohort study. Lancet 2009; 374: 12621270.
  • 9
    De Maeyer J., Vanderplasschen W., Camfield L., Vanheule S., Sabbe B., Broekaert E. A good quality of life under the influence of methadone: a qualitative study among opiate-dependent individuals. Int J Nurs Stud 2011; 48: 12441257.
  • 10
    Bell J. Maintenance pharmacological treatment of opiate dependence. Br J Clin Pharmacol 2013; doi: 10.1111/bcp.12051.
  • 11
    Lobmaier P., Kunøe N., Gossop M., Katevoll T., Waal H. Naltrexone implants compared to methadone: outcomes 6 months after prison release. Eur Addict Res 2010; 16: 139145.
  • 12
    Kenny P. J., Chen S. A., Kitamura O., Markou A., Koob G. F. Conditioned withdrawal drives heroin consumption and decreases reward sensitivity. J Neurosci 2006; 26: 58945900.
  • 13
    Faggiano F., Vigna-Taglianti F., Versino E., Lemma P. Methadone maintenance at different dosages for opioid dependence. Cochrane Database Syst Rev 2003; (3): CD002208.
  • 14
    Comer S. D., Sullivan M. A., Yu E., Rothenberg J. L., Kleber H. D., Kampman K. et al. Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch Gen Psychiatry 2006; 63: 210218.
  • 15
    Hulse G. K., Tait R. J., Comer S. D., Sullivan M. A., Jacobs I. G., Arnold-Reed D. Reducing hospital presentations for opioid overdose in patients treated with sustained release naltrexone implants. Drug Alcohol Depend 2005; 79: 351357.